Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

JW Pharmaceutical145 enrolled

Overview

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

145

Conditions

Dyslipidemia

Interventions

JW0108 + C2407DRUG

JW0108 + C2407

JW0108 + C2407 placeboDRUG

JW0108 + C2407 placebo

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age of 19 years old at the time of written informed consent * Patients with dyslipidemia Exclusion Criteria: * Secondary dyslipidemia * Patient who does not meet the specified TG, LDL-C level

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Percent change from baseline in LDL-C

Check LDL-C

Time frame: Week 8

Secondary Outcomes

Efficacy and Safety: Change from baseline in LDL-C (mg/dL)

Check LDL-C

Time frame: Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.